50% Off! Beat the market in 2025 with InvestingProCLAIM SALE

Vigil Neuroscience director Budd Haeberlein buys $20,520 in shares

Published 12/20/2024, 07:46 AM
VIGL
-

WATERTOWN, MA—Samantha L. Budd Haeberlein, a director at Vigil Neuroscience, Inc. (NASDAQ:VIGL), purchased 12,000 shares of the company's common stock on December 19, according to a recent SEC filing. The purchase comes as the stock trades near its 52-week low of $1.60, having declined over 57% in the past six months. The shares were acquired at a weighted average price of $1.71, with transaction prices ranging from $1.69 to $1.72. This acquisition brings Budd Haeberlein's total holdings to 12,000 shares, valued at approximately $20,520. According to InvestingPro analysis, the stock appears undervalued at current levels, with technical indicators suggesting oversold conditions. Get deeper insights into insider trading patterns and 14 additional ProTips with an InvestingPro subscription.

In other recent news, Vigil Neuroscience has received significant attention in the biotechnology sector due to its advancements in Alzheimer's treatment. The company's VG-3927 program, a potential Alzheimer's treatment, was given the green light by the U.S. Food and Drug Administration (FDA) to potentially increase the drug's exposure limit in its ongoing study. This decision came after Vigil Neuroscience provided a complete response to the FDA, marking a significant step forward for the program.

The company has also been rated Outperform by William Blair and Guggenheim, with William Blair setting a fair value of $18.67 per share. JMP Securities and Mizuho (NYSE:MFG) Securities also maintained their positive ratings, with stock price targets of $23.00 and $13.00 respectively. These ratings reflect the analysts' confidence in Vigil Neuroscience's potential to succeed in the challenging field of neurodegenerative diseases.

Vigil Neuroscience is also making strategic adjustments in its clinical development. The company has decided to forgo an interim analysis for its IGNITE trial, which is assessing the efficacy of iluzanebart in treating a rare neurodegenerative disease, in favor of a comprehensive 12-month final analysis. These recent developments underscore Vigil Neuroscience's commitment to its research initiatives and its potential to address the needs of a broad patient population.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.